首页> 美国卫生研究院文献>Journal of Clinical Laboratory Analysis >Diagnostic usefulness of serum interleukin 6 (IL‐6) and C‐reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis
【2h】

Diagnostic usefulness of serum interleukin 6 (IL‐6) and C‐reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis

机译:血清白细胞介素6(IL-6)和C反应蛋白(CRP)在胰腺癌和慢性胰腺炎之间分化中的诊断有用性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Previous studies have shown elevated serum levels of interleukin 6 (IL‐6) and C‐reactive protein (CRP) in patients with pancreatic cancer (PC). The aim of this study was to assess the diagnostic usefulness of pretreatment serum levels of IL‐6 and CRP to differentiate between PC and chronic pancreatitis (CP) patients. Serum levels of CRP, IL‐6, carcinoembryonic antigen (CEA), and carbohydrate antigen 19‐9 (CA 19‐9) were determined in 78 patients with PC before surgery, in 45 patients with CP, and in 70 healthy controls. Serum levels of all the proteins tested were significantly higher in cancer patients when compared with CP and healthy subjects, and increased in more advanced tumor stages. Concentrations of IL‐6 were significantly higher in nonresectable tumors and in patients who died during the 2‐year observation period. Area under receiver operating characteristic curve for IL‐6 was higher than for other substances tested in the differentiation between PC and CP. Cox's univariate analysis revealed serum IL‐6 as a significant prognostic factor of patients' survival. Our findings suggest higher diagnostic usefulness of serum IL‐6 than CRP, CEA, and CA 19‐9 in the diagnosis and prognosis of patients with PC and in the differentiation with CP. J. Clin. Lab. Anal. 24:256–261, 2010. © 2010 Wiley‐Liss, Inc.
机译:以前的研究显示胰腺癌(PC)患者的白细胞介素6(IL-6)和C反应蛋白(CRP)的血清水平升高。本研究的目的是评估预处理血清IL-6和CRP水平的诊断有用性,以区分PC和慢性胰腺炎(CP)患者。在手术前的78例PC患者中,在45例CP患者中,在45例CP患者和70例健康对照组中,测定了在78例PC患者中测定了血清CRP,IL-6,癌胚抗原19-9(CA 19-9)。与CP和健康受试者相比,癌症患者的所有蛋白质的血清水平显着高,并且在更先进的肿瘤阶段增加。在2年观测期间,非可识别肿瘤和患者的IL-6浓度显着高。接收器下的区域,IL-6的操作特征曲线高于在PC和CP之间进行分化中测试的其他物质。 Cox的单变量分析显示血清IL-6作为患者存活的显着预后因素。我们的研究结果表明,血清IL-6的诊断有用性高于CRP,CEA和CA 19-9在PC患者和CP分化中的诊断和预后。 J. Clin。实验室。肛门。 24:256-261,2010。©2010 Wiley-Liss,Inc。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号